Citation Report

List of articles citing

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

DOI: 10.1056/nejmoa1611770
New England Journal of Medicine, 2017, 376, 429-439.

#	Paper	IF	Citations
496	Increased Vasoocclusive Crises in "O" Blood Group Sickle Cell Disease Patients: Association with Underlying Thrombospondin Levels. **2017**, 9, e2017028		2
495	Go with the Flow. *New England Journal of Medicine*, **2017**, 376, 485-487	59.2	2
494	Unclogging sickle cell anaemia. **2017**, 18, 214		3
493	Hypoxia-enhanced adhesion of red blood cells in microscale flow. **2017**, 24, e12374		28
492	Sickle Cell Disease. *New England Journal of Medicine*, **2017**, 376, 1561-1573	59.2	561
491	Heme-mediated cell activation: the inflammatory puzzle of sickle cell anemia. *Expert Review of Hematology*, **2017**, 10, 533-541	2.8	19
490	Crizanlizumab in Sickle Cell Disease. *New England Journal of Medicine*, **2017**, 376, 1795-1796	59.2	9
489	[A new therapeutic era in sickle cell disease]. **2017**, 38, 569-571		
488	Prasugrel hydrochloride for the treatment of sickle cell disease. **2017**, 26, 865-872		8
487	Treating sickle cell disease by targeting HbS polymerization. *Blood*, **2017**, 129, 2719-2726	2.2	112
486	Circulating tumor cells and coagulation-Minireview. **2017**, 114, 33-42		12
485	Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention. *Expert Review of Hematology*, **2017**, 10, 875-890	2.8	4
484	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. **2017**, 92, 1333-1339		42
483	Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes. **2017**, 2, 484-497		29
482	Prothrombotic aspects of sickle cell disease. **2017**, 15, 1307-1316		29
481	Targeting novel mechanisms of pain in sickle cell disease. *Blood*, **2017**, 130, 2377-2385	2.2	47
480	Sickle Mice Are Sensitive to Hypoxia/Ischemia-Induced Stroke but Respond to Tissue-Type Plasminogen Activator Treatment. **2017**, 48, 3347-3355		7

479	Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. **2017**, 96, 1373-1377		16
478	Ser/Thr protein kinase B NADPH oxidase 2 signaling in thromboinflammation. **2017**, 24, 460-466		3
477	Targeting novel mechanisms of pain in sickle cell disease. **2017**, 2017, 546-555		11
476	Evolving treatment paradigms in sickle cell disease. **2017**, 2017, 440-446		9
475	Glycoprotein Ib inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease. *Blood Advances*, **2017**, 1, 1712-1716	7.8	13
474	Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. *Blood Advances*, **2017**, 1, 1598-1616	7.8	23
473	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. *Blood Advances*, **2017**, 1, 1645-1649	7.8	28
472	Rheumatoid Arthritis in Sickle-Cell Population: Pathophysiologic Insights, Clinical Evaluation and Management. **2017**, 7,		6
471	Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project. **2018**, 19, 1972-1981		0
470	Hemoglobinopathies enetically diverse, clinically complex, and globally relevant. **2018**, 11, 235-240		0
469	Autonomic nervous system involvement in sickle cell disease. **2018**, 68, 251-262		15
468	Inflammation in sickle cell disease. **2018**, 68, 263-299		76
467	The Platelet Lifeline to Cancer: Challenges and Opportunities. **2018**, 33, 965-983		202
466	Sickle Cell Anemia and Its Phenotypes. **2018**, 19, 113-147		34
465	GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. *Expert Review of Hematology*, **2018**, 11, 169-184	2.8	17
464	Mast cell-neural interactions contribute to pain and itch. **2018**, 282, 168-187		99
463	Platelets at the crossroads of thrombosis, inflammation and haemolysis. *British Journal of Haematology*, **2018**, 180, 761-767	4.5	18
462	Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease. **2018**, 60, 73-82.e3		3

461	Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. **2018**, 93, E99-E101		3
460	Antibodies to watch in 2018. **2018**, 10, 183-203		203
459	Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling. **2018**, 55, 68-75		9
458	Sickle cell disease. **2018**, 4, 18010		373
457	Pathobiology of Sickle Cell Disease Vaso-occlusion and Targeted Therapies. **2018**, 41-64		1
456	State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease. **2018**, 20, 29-42		6
455	Ethical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease. **2018**, 24, 219-227		22
454	Current Non-HSCT Treatments for SCD. **2018**, 65-86		
453	Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. *Expert Review of Hematology*, **2018**, 11, 45-55	2.8	13
452	Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon. *British Journal of Haematology*, **2018**, 180, 134-146	4.5	22
451	Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. **2018**, 103, e50-e54		13
450	New insights into the pathophysiology and development of novel therapies for sickle cell disease. **2018**, 2018, 493-506		14
449	Sickle Cell Disease: Advances in Treatment. **2018**, 18, 377-389		37
448	Advances in the Treatment of Sickle Cell Disease. *Mayo Clinic Proceedings*, **2018**, 93, 1810-1824	6.4	32
447	Neutrophils, NETs, and immunothrombosis. *Blood*, **2018**, 132, 1360-1361	2.2	17
446	Sickle Cell Disease and Pregnancy. **2018**, 791-801		
445	How I treat the older adult with sickle cell disease. *Blood*, **2018**, 132, 1750-1760	2.2	14
444	A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study. **2018**, 93, 1493-1500		11

443	Red blood cell transfusion therapy for sickle cell patients with frequent painful events. **2018**, 65, e27423		9
442	Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. **2018**, 2018, 482-492		13
441	Determinants of hematology-oncology trainees' postfellowship career pathways with a focus on nonmalignant hematology. *Blood Advances*, **2018**, 2, 361-369	7.8	6
440	The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase. *Blood Advances*, **2018**, 2, 2672-2680	7.8	33
439	Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges. **2018**, 65, e27263		19
438	How I diagnose and treat venous thromboembolism in sickle cell disease. *Blood*, **2018**, 132, 1761-1769	2.2	20
437	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. **2018**, 65, e27228		34
436	A Scientific Renaissance: Novel Drugs in Sickle Cell Disease. **2018**, 65, 445-464		1
435	The Epidemiology and Management of Lung Diseases in Sickle Cell Disease: Lessons Learned from Acute and Chronic Lung Disease in Cystic Fibrosis. **2018**, 65, 481-493		2
434	Targeting pain at its source in sickle cell disease. **2018**, 315, R104-R112		14
433	Erythrocytes and Vascular Function: Oxygen and Nitric Oxide. **2018**, 9, 125		68
432	Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction. *PLoS ONE*, **2018**, 13, e0196455	3.7	59
431	A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. *New England Journal of Medicine*, **2018**, 379, 226-235	59.2	212
430	Advances in new drug therapies for the management of sickle cell disease. **2018**, 6, 329-343		9
429	The Glycoscience of Immunity. **2018**, 39, 523-535		39
428	Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. **2018**, 78, 3560-3573		35
427	Glycan Therapeutics: Resurrecting an Almost Pharma-Forgotten Drug Class. **2018**, 1, 1800082		10
426	Emerging disease-modifying therapies for sickle cell disease. **2019**, 104, 1710-1719		32

425	New and emerging treatments for vaso-occlusive pain in sickle cell disease. *Expert Review of Hematology*, **2019**, 12, 857-872	2.8	4
424	Accelerating the Science of SCD Therapies-Is a Cure Possible?. *JAMA - Journal of the American Medical Association*, **2019**, 322, 921-922	27.4	4
423	A Growing Population of Older Adults with Sickle Cell Disease. **2019**, 35, 349-367		3
422	Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic. **2019**, 203, 107393		9
421	"Stuck on sugars - how carbohydrates regulate cell adhesion, recognition, and signaling". **2019**, 36, 241-257		51
420	Platelet-Neutrophil Crosstalk in Atherothrombosis. **2019**, 119, 1274-1282		40
419	Targeting P-Selectin Adhesion Molecule in Molecular Imaging: P-Selectin Expression as a Valuable Imaging Biomarker of Inflammation in Cardiovascular Disease. **2019**, 60, 1691-1697		10
418	Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease. **2019**, 39, 1095-1104		13
417	Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease. *Journal of Clinical Medicine*, **2019**, 8,	5.1	3
416	Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation of the Microvasculature the Trigger?. *Journal of Clinical Medicine*, **2019**, 8,	5.1	14
415	Novel Reversible Fluorescent Glycan Linker for Functional Glycomics. **2019**, 30, 2897-2908		10
414	Sickle cell disease in the era of precision medicine: looking to the future. **2019**, 4, 357-367		2
413	Mechanisms of haemolysis-induced kidney injury. **2019**, 15, 671-692		47
412	Validation of a composite vascular high-risk profile for adult patients with sickle cell disease. **2019**, 94, E312-E314		2
411	T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?. *Expert Review of Hematology*, **2019**, 12, 733-752	2.8	4
410	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. **2019**, 16, e17-e32		15
409	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). **2019**, 85, 105835		4
408	Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date. **2019**, 10, 307-311		7

407	Translational glycobiology: from bench to bedside. **2019**, 112, 424-427		4
406	Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease. **2019**, 244, 171-182		8
405	cGMP modulation therapeutics for sickle cell disease. **2019**, 244, 132-146		14
404	Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. **2019**, 102, 319-330		18
403	Redox Signaling in Sickle Cell Disease. **2019**, 9, 26-33		7
402	Epidemiological, clinical, and severity characterization of sickle cell disease in a population from the Brazilian Amazon. **2019**, 12, 204-210		5
401	[What's new in diagnostics and treatment of hemoglobinopathies?]. **2019**, 144, 719-723		
400	Biologic roles of the ABH and Lewis histo-blood group antigens part II: thrombosis, cardiovascular disease and metabolism. **2019**, 114, 535-552		32
399	Sickle cell disease: Clinical presentation and management of a global health challenge. **2019**, 37, 100580		22
398	Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD. *Blood*, **2019**, 134, 579-590	2.2	14
397	Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. **2019**, 5, 20		32
396	Mast Cells Induce Blood Brain Barrier Damage in SCD by Causing Endoplasmic Reticulum Stress in the Endothelium. **2019**, 13, 56		17
395	P-selectin plays a role in haem-induced acute lung injury in sickle mice. *British Journal of Haematology*, **2019**, 186, 329-333	4.5	11
394	Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. **2019**, 189, 706-718		19
393	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. **2019**, 116, 6280-6285		51
392	Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. **2019**, 26, 116-124		19
391	Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development. **2019**, 33, 355-371		9
390	Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. **2019**, 58, 1295-1307		6

389	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. **2019**, 2019, 397-406		14
388	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. *Blood*, **2019**, 134, 1902-1911	2.2	13
387	Role of the coagulation system in the pathogenesis of sickle cell disease. *Blood Advances*, **2019**, 3, 3170-3180	7.8	19
386	End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. *Blood Advances*, **2019**, 3, 3982-4001	7.8	25
385	Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment. **2019**, 21, 145		55
384	The Sickle Cell Disease Ontology: enabling universal sickle cell-based knowledge representation. **2019**, 2019,		6
383	Improving the Standards of Reporting of Clinical Trial Data. **2019**, 2168479019879099		
382	P-Selectin Is Critical for De Novo Pulmonary Arterial Thrombosis Following Blunt Thoracic Trauma. **2019**, 86, 583-591		8
381	Vascular endothelial cell expression of JAK2 is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. **2019**, 104, 70-81		49
380	Critical role of C5a in sickle cell disease. **2019**, 94, 327-337		29
379	Smooth Muscle Cells: A Novel Site of P-Selectin Expression with Pathophysiological and Therapeutic Relevance in Pulmonary Hypertension. **2019**, 199, 1307-1309		6
378	Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. *British Journal of Haematology*, **2019**, 184, 269-278	4.5	15
377	Anemia in the Young and Old. **2019**,		
376	New Therapeutic Options for the Treatment of Sickle Cell Disease. **2019**, 11, e2019002		16
375	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. **2019**, 104, 919-928		22
374	New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. **2019**, 104, 3-6		12
373	Therapeutic strategies for sickle cell disease: towards a multi-agent approach. **2019**, 18, 139-158		71
372	Emerging pharmacotherapeutic approaches for the management of sickle cell disease. **2019**, 20, 173-186		11

371	Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. **2019**, 94, 55-61		50
370	Hemostatic Aspects of Sickle Cell Disease. **2019**, 819-842		
369	Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia. **2020**, 40, 100637		6
368	Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention. *British Journal of Haematology*, **2020**, 188, 488-493	4.5	9
367	Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease. **2020**, 107, 140-146		3
366	Treating sickle cell anemia: A new era dawns. **2020**, 95, 338-342		10
365	Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet Splice QTL. **2020**, 126, 501-516		15
364	Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?. **2020**, 29, 23-31		9
363	[Advances in sickle cell disease treatments: Towards targeted therapies]. **2020**, 41, 73-77		1
362	Passive Monoclonal and Polyclonal Antibody Therapies. **2020**, 251-348		5
361	Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises. **2020**, 127, 154933		18
360	Managing patients with sickle cell disease in primary care. **2020**, 33, 21-28		1
359	Gene Therapy of the Hemoglobinopathies. **2020**, 4, e479		9
358	Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease. **2020**, 10, 16514		2
357	Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. **2020**, 95, E338-E339		5
356	Douleur aigu**2020**, 21, S1-S5		
355	Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease. **2020**, 11, 2041		5
354	Parents of Children with Sickle Cell Disease Are Interested in Preimplantation Genetic Testing. **2020**, 223, 178-182.e2		5

353	What is the future of patient-reported outcomes in sickle-cell disease?. *Expert Review of Hematology*, **2020**, 13, 1165-1173	2.8	2
352	Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. **2020**, 11, 2040620720955000		7
351	Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. **2020**, 3, e201737		37
350	Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents. **2020**, 63, 14724-14739		2
349	An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling. **2020**, 10,		3
348	Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with´sickle cell anemia. **2020**, 10, 18982		1
347	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. **2020**, 7, e902-e911		3
346	HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation. *Blood Advances*, **2020**, 4, 4560-4572	7.8	8
345	Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?. *Blood Advances*, **2020**, 4, 3457-3465	7.8	5
344	Novel Approaches to Fine-Tune Therapeutic Targeting of Platelets in Atherosclerosis: A Critical Appraisal. **2020**, 120, 1492-1504		3
343	Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. **2020**, 17, 597-617		45
342	Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. **2020**, 3, e2010874		15
341	The Gut Microbiome Regulates Psychological-Stress-Induced Inflammation. **2020**, 53, 417-428.e4		29
340	Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology. **2020**, 21,		4
339	Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease. **2020**, 105, 2407-2419		1
338	Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. *Blood Advances*, **2020**, 4, 3688-3698	7.8	11
337	Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. **2020**, 92, 11-18.e1		12
336	Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. **2020**, 10, e034147		4

335	Interleukin-1 receptor inhibition reduces stroke size in a murine model of sickle cell disease. **2021**, 106, 2469-2477		1
334	The molecular basis for the prothrombotic state in sickle cell disease. **2020**, 105, 2368-2379		12
333	MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease. **2020**, 4, e452		1
332	Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease: A Qualitative Study. **2020**, 3, e206742		6
331	Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers. **2020**, 23, 1345-1355		7
330	Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice. *Blood Advances*, **2020**, 4, 4102-4112	7.8	4
329	Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. **2020**, 26, 1076029620955240		5
328	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. **2020**, 10, 20277		4
327	Cadherins, Selectins, and Integrins in CAM-DR in Leukemia. **2020**, 10, 592733		9
326	Sickle cell disease as a vascular disorder. *Expert Review of Hematology*, **2020**, 13, 645-653	2.8	2
325	Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. *Blood*, **2020**, 135, 1783-1787	2.2	19
324	Sickle cell vaso-occlusion: the clot thickens. *Blood*, **2020**, 135, 1726-1727	2.2	
323	Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties. *Blood*, **2020**, 136, 247-256	2.2	11
322	P-selectin blockade in COVID-19-related ARDS. **2020**, 318, L1237-L1238		24
321	Crizanlizumab. **2020**, 001857872092537		1
320	Small molecule therapeutics to treat the β-globinopathies. **2020**, 27, 129-140		6
319	Advances in Sickle Cell Disease Management. **2020**, 67, 57-71		3
318	Recent Advances in the Treatment of Sickle Cell Disease. **2020**, 11, 435		40

317	Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis. **2020**, 52, 102481		1
316	American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Advances*, **2020**, 4, 2656-2701	7.8	53
315	Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. **2020**, 83, 102424		17
314	Pathophysiology and recent therapeutic insights of sickle cell disease. **2020**, 99, 925-935		7
313	Emerging therapies in sickle cell disease. *British Journal of Haematology*, **2020**, 190, 149-172	4.5	16
312	Is sickle cell disease-related neurotoxicity a systemic endotheliopathy?. **2020**, 13, 111-115		
311	Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update. **2020**, 13, 91-97		1
310	A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease. **2020**, 24, 17		2
309	Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape. **2020**, 24, 439-450		4
308	Treating sickle cell anemia. **2020**, 367, 1198-1199		16
307	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. *PLoS ONE*, **2020**, 15, e0229710	3.7	5
306	Cardiac causes of hypoxia in sickle cell disease. **2020**, 56, 101192		
305	Crizanlizumab: First Approval. **2020**, 80, 79-84		18
304	Blood rheology biomarkers in sickle cell disease. **2020**, 245, 155-165		8
303	Innate immune cells, major protagonists of sickle cell disease pathophysiology. **2020**, 105, 273-283		11
302	The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. **2020**, 12, e2020010		20
301	Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. **2020**, 40, 525-534		5
300	Tandem P-selectin glycoprotein ligand immunoglobulin prevents lung vaso-occlusion in sickle cell disease mice. **2020**, 84, 1-6.e1		2

299	Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. **2020**, 40, 535-543		8
298	Improving the Standards of Reporting of Clinical Trial Data. **2020**, 54, 717-722		
297	The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. **2020**, 105, 237-246		33
296	Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019. **2020**, 202, 22-28		3
295	P-selectin-deficient mice to study pathophysiology of sickle cell disease. *Blood Advances*, **2020**, 4, 266-273	3.8	14
294	An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research. **2021**, 8, 99-106		4
293	Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. *Blood*, **2021**, 137, 2010-2020	2.2	4
292	Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. *Blood*, **2021**, 137, 1145-1153	1.5	16
291	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. *New England Journal of Medicine*, **2021**, 384, 252-260	59.2	292
290	Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease. **2021**, 41, 769-782		6
289	L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality. **2021**, 96, E38-E40		7
288	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. **2021**, 27, 167.e1-167.e12		1
287	A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?. **2021**, 51, 711-719		1
286	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. **2021**, 64, 326-342		10
285	Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease. **2021**, 96, E29-E32		9
284	What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?. **2021**, 22, 5-8		
283	Can red blood cell function assays assess response to red cell-modifying therapies?. **2021**,		1
282	The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease. **2020**, 11, 561917		15

281	Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. **2020**, 11, 613278		9
280	Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. **2021**, 12, 20406207211001136		2
279	Lipids | Glycan-Dependent Cell Adhesion Processes. **2021**, 654-662		
278	The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. **2021**, 20, 217-243		60
277	Therapeutic gene editing strategies using CRISPR-Cas9 for the hemoglobinopathies. **2020**, 35, 115-134		2
276	Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. **2021**, 41, 48-57		6
275	Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. *British Journal of Haematology*, **2021**, 192, 761-768	4.5	9
274	Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for hemoglobinopathies. **2021**, 28, 191-208		4
273	Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling , and prolongs survival of sickle cell mice under hypoxia. **2021**,		
272	Stroke and presence of patent foramen ovale in sickle cell disease. **2021**, 52, 889-897		2
271	Determinants of Use of Biotherapeutics in sub-Saharan Africa. **2021**, 42, 75-84		3
270	Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged . **2021**, 68, e28977		0
269	Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome. **2021**, 12, 101-114		2
268	Biophysical and rheological biomarkers of red blood cell physiology and pathophysiology. **2021**, 28, 138-149		5
267	Gene therapy for hemoglobinopathies. **2021**, 60, 103061		0
266	P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab. **2021**, 14, 849-856		6
265	Longitudinal Assessment of Retinal Thinning in Adults With and Without Sickle Cell Retinopathy Using Spectral-Domain Optical Coherence Tomography. **2021**, 139, 330-337		3
264	American Society of Hematology 2020 Podcast Collection: Sickle Cell Anaemia. **2021**, 38, 1-7		

263	The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US. **2021**, 37, 761-768		1
262	Voxelotor for the treatment of sickle cell disease. *Expert Review of Hematology*, **2021**, 14, 253-262	2.8	1
261	Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. **2021**, 12, 636609		1
260	Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm. **2021**, 127, 498-506		2
259	Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms. **2021**, 35, 935-955		4
258	Cardiac pathophysiology in sickle cell disease. **2021**, 52, 248-259		1
257	MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. *Blood Advances*, **2021**, 5, 1388-1402	7.8	1
256	Quantification of intermittent retinal capillary perfusion in sickle cell disease. **2021**, 12, 2825-2840		0
255	Current Clinical Investigations in Myelofibrosis. **2021**, 35, 353-373		2
254	Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients. **2021**, 12, 663886		1
253	Preclinical evaluation for engraftment of CD34 cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models. **2021**, 2, 100247		4
252	Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction. **2021**, 11, 1785-1803		5
251	Advances in Sickle Cell Disease Treatments. **2021**, 28, 2008-2032		3
250	2019-2020 Drug Updates in Hematologic Malignancies. **2021**, 12, 279-283		1
249	Therapeutic Strategies for the Treatment of Sickle Cell Disease. 1-31		1
248	Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms. **2021**, 16, 304-313		9
247	Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease. **2021**, 37, 209-215		1
246	Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. **2021**, 35, 305-324		1

245	Sickle cell vaso-occlusion: The dialectic between red cells and white cells. **2021**, 246, 1458-1472		3
244	P-selectin deficiency promotes liver senescence in sickle cell disease mice. *Blood*, **2021**, 137, 2676-2680	2.2	4
243	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. *Blood Advances*, **2021**, 5, 2403-2411	7.8	6
242	Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. **2021**, 8, e334-e343		7
241	Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark. **2021**, 8, e307-e309		0
240	P-selectin and sickle cell disease: a balancing act. *Blood*, **2021**, 137, 2573-2574	2.2	1
239	A long-half-life, high-affinity P-selectin inhibitor. *Blood*, **2021**, 138, 1096-1097	2.2	1
238	Gene therapy as the new frontier for Sickle Cell Disease. **2021**,		1
237	A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis. *Blood*, **2021**, 138, 1182-1193	2.2	3
236	Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. **2021**, 11, 10838		3
235	Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease. **2021**, 8971900211026644		1
234	The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease. **2021**, 5, e604		1
233	Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. **2021**, 13,		6
232	Innovative Treatments for Rare Anemias. **2021**, 5, e576		0
231	Microvascular thrombosis and clinical implications. **2021**, 156, 609-614		
230	Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. **2021**, 13,		12
229	Research in Sickle Cell Disease: From Bedside to Bench to Bedside. **2021**, 5, e584		5
228	Inflammation, Infection and Venous Thromboembolism. **2021**, 128, 2017-2036		23

227	Manifestations of HbSE sickle cell disease: a systematic review. **2021**, 19, 262		4
226	[Microvascular thrombosis and clinical implications]. **2021**, 156, 609-614		3
225	Plasma P-selectin is an early marker of thromboembolism in COVID-19. **2021**,		1
224	Biomarkers for the central nervous system complications of sickle cell disease: are we there yet?. **2021**, 15, e2100026		
223	Gene therapy for sickle cell disease: moving from the bench to the bedside. *Blood*, **2021**, 138, 932-941	2.2	8
222	A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease. *Blood Advances*, **2021**, 5, 2839-2851	7.8	2
221	Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what. **2021**, 50, 100868		1
220	Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. **2021**, 96, 1223-1231		6
219	Benserazide racemate and enantiomers induce fetal globin gene expression in vivo: Studies to guide clinical development for beta thalassemia and sickle cell disease. **2021**, 89, 102561		5
218	Content validation of a self-report daily diary in patients with sickle cell disease. **2021**, 5, 63		0
217	Antibiotics to modify sickle cell disease vaso-occlusive crisis?. **2021**, 50, 100867		1
216	Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. **2021**, 48, 100805		3
215	Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease. **2021**, 13,		2
214	Pain in sickle cell disease: current and potential translational therapies. **2021**, 234, 141-158		0
213	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. **2021**, 27, 885-907		0
212	Hemolysis: Mechanism and clinico-biological consequences. **2021**, 28, 364-366		0
211	The gut microbiome in sickle cell disease: Characterization and potential implications. *PLoS ONE*, **2021**, 16, e0255956	3.7	2
210	Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. **2021**, 19, 397		5

209	Neutrophil extracellular traps: a role in inflammation and dysregulated hemostasis as well as in patients with COVID-19 and severe obstetric pathology. **2021**, 15, 335-350		2
208	A reanalysis of pain crises data from the pivotal l-glutamine in sickle cell disease trial. **2021**, 110, 106546		0
207	Management of refractory chronic pain in sickle cell disease with intrathecal drug delivery system. **2021**,		
206	How I approach disease-modifying therapy in children with sickle cell disease in an era of novel therapies. **2021**, 68, e29363		1
205	Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease. *British Journal of Haematology*, **2021**, 194, 1074-1082	4.5	1
204	P-selectin targeted RAGE-shRNA lipoplexes alleviate atherosclerosis-associated inflammation. **2021**, 338, 754-772		4
203	Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care. **2021**, 8, e744-e755		2
202	Les traitements de la drépanocytose : hydroxyurée, allogreffe et nouvelles approches. **2021**, 2, 397-397		
201	Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort. **2021**, 92, 102612		0
200	RNA binding proteins: Linking mechanotransduction and tumor metastasis. **2021**, 496, 30-40		4
199	Sickle cell disease: progress towards combination drug therapy. *British Journal of Haematology*, **2021**, 194, 240-251	4.5	4
198	Sickle cell disease in pregnancy and anaesthetic implications: A narrative review. **2021**, 11, 70		1
197	Effect of Natural Products on Improvement of Blood Pathophysiology for Management of Sickle Cell Anemia. **2020**, 51-65		2
196	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. **2019**, 4,		59
195	Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. **2017**, 2,		43
194	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. **2018**, 3,		87
193	The multifaceted role of ischemia/reperfusion in sickle cell anemia. **2020**, 130, 1062-1072		24
192	Mechanisms of pain in sickle cell disease. **2021**, 15, 213-220		4

191	Optimal disease management and health monitoring in adults with sickle cell disease. **2019**, 2019, 505-512		4
190	Drug Therapies for the Management of Sickle Cell Disease. **2020**, 9,		12
189	Targeting P-selectin blocks neuroblastoma growth. **2017**, 8, 86657-86670		10
188	Factors Influencing Motivation and Engagement in Mobile Health Among Patients With Sickle Cell Disease in Low-Prevalence, High-Income Countries: Qualitative Exploration of Patient Requirements. **2020**, 7, e14599		8
187	MEK1/2 as a Therapeutic Target in Sickle Cell Disease. **2019**, 6,		2
186	Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance. **2020**, 105, 2380-2390		16
185	Therapeutic advances in sickle cell disease in the last decade. **2017**, 145, 708-712		2
184	Sickle cell disease: Progress made & challenges ahead. **2020**, 151, 505-508		4
183	coreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials. **2021**, 21, 219		0
182	Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease. **2021**,		0
181	Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. *British Journal of Haematology*, **2021**, 195, e150-e153	4.5	0
180	Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. **2021**, 1-16		0
179	Casting a NET on cancer: the multiple roles for neutrophil extracellular traps in cancer. **2022**, 29, 53-62		1
178	Anemia at the Extremes of Life: Congenital Hemolytic Anemia. **2019**, 95-135		
177	Sickle Cell Anemia: A review on the most severe form of Sickle Cell Disease. **2019**, 02,		
176	Factors Influencing Motivation and Engagement in Mobile Health Among Patients With Sickle Cell Disease in Low-Prevalence, High-Income Countries: Qualitative Exploration of Patient Requirements (Preprint).		
175	Pyridoxamine: another vitamin for sickle cell disease?. **2020**, 105, 2348-2350		1
174	Sickle Cell Disease. **2021**, 65-89		

173	Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. **2020**, 5,		2
172	The Anti-Sickling Properties of Medicinal Plants, Insights in Botanical Medicine*. **2021**, 11, 165-189		
171	Neugeborenenscreening auf Sichelzellkrankheit in Deutschland. **2021**, 81, 1197-1199		
170	Five Diseases That Are Devastating the African American Population. **2020**, 1-31		
169	Anemias hemolíticas adquiridas y congénitas. **2020**, 13, 1201-1209		
168	Review of Medication Therapy for the Prevention of Sickle Cell Crisis. **2018**, 43, 417-437		4
167	Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease. **2020**, 11, 873-877		
166	Anemia. **2021**,		
165	Novel histone deacetylase inhibitor CT-101 induces γ-globin gene expression in sickle erythroid progenitors with targeted epigenetic effects. **2021**, 93, 102626		1
164	A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence. *British Journal of Haematology*, **2021**,	4.5	2
163	Nationwide retrospective study of critically ill adults with sickle cell disease in France. **2021**, 11, 23132		1
162	Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Outcomes. The Experience of a Single Thalassemia and Sickle Cell Unit in a University Hospital. **2021**, 1-6		
161	Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation. **2022**, 219,		1
160	Unterarmschmerzen bei einem Jungen aus dem Irak. 1		
159	Dietary alpha-linolenic acid reduces platelet activation and collagen-mediated cell adhesion in sickle cell disease mice. **2021**,		1
158	Mucin-Type O-GalNAc Glycosylation in Health and Disease. **2021**, 1325, 25-60		5
157	l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?. **2022**, 100925		0
156	Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease. **2020**, 11, 873-877		0

155	Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.. **2021**, 6, 935-945		2
154	Computational Genomics in the Era of Precision Medicine: Applications to Variant Analysis and Gene Therapy.. **2022**, 12,		0
153	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.. **2022**,		2
152	Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.. **2022**, 10781552211072468		
151	Evolving Strategies in the Management of Sickle Cell Disease in the 21st Century and the Role of the Pediatrician.. **2022**, 51, e34-e39		
150	Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.. **2022**, 22, 42		1
149	Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients.. **2022**, 13,		0
148	Neutrophil-Platelet Interactions as Novel Treatment Targets in Cardiovascular Disease.. **2021**, 8, 824112		3
147	Clinical impact of glycans in platelet and megakaryocyte biology.. *Blood*, **2022**,	2.2	1
146	Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	3
145	Long-term outcomes of lentiviral gene therapy for the haemoglobinopathies: the HGB-205 trial.. **2022**,		8
144	Pregnancy Outcomes with Hydroxyurea Use in Women with Sickle Cell Disease.. **2022**,		3
143	Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis and management.. *Expert Review of Hematology*, **2022**,	2.8	1
142	Can galectin-3 be used to predict the severity of vasoocclusive crisis in patients with sickle cell anaemia?. **2022**, 9,		
141	Neugeborenenscreening auf Sichelzellkrankheit. **2022**, 22, 09-15		
140	A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.. *Blood*, **2022**,	2.2	3
139	Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor.. *British Journal of Haematology*, **2022**,	4.5	
138	Voxelotor: A new kid on the block in the treatment of sickle cell disease.. **2022**,		

137	Black Americans' willingness to participate in pediatric sickle cell clinical trials: A retrospective, systematic review.. **2022**, e29580		
136	A Vascular Necrosis of Femoral Head in Sickle Cell Anemia.		
135	The nephropathy of sickle cell trait and sickle cell disease.. **2022**,		1
134	Hemoglobinopathies. **2022**, 68, 3-11		
133	P- and E- selectin in Venous Thrombosis and Non-Venous Pathologies.. **2022**,		0
132	Advances in the Management of Sickle Cell Disease: New Concepts and Future Horizons.. **2022**, 27, 206-213		0
131	Knowledge and Awareness of Sickle Cell Anemia: Cross Sectional Study among the General Population in Saudi Arabia. 69-74		
130	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. **2022**, 15, 378-433		0
129	Possible Role of P-selectin Adhesion in Long-COVID: A Comparative Analysis of a Long-COVID Case Versus an Asymptomatic Post-COVID Case.		
128	Microfluidic Methods to Advance Mechanistic Understanding and Translational Research in Sickle Cell Disease.. **2022**,		
127	Renin-Angiotensin Blockade Reduces Readmission for Acute Chest Syndrome in Sickle Cell Disease.. **2022**, 14, e23567		
126	Advances in the diagnosis and treatment of sickle cell disease.. **2022**, 15, 20		4
125	Treatment of sickle cell disease: Beyond hydroxyurea. 1-6		
124	Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.. **2022**, e29607		0
123	Regional anesthesia for sickle cell disease vaso-occlusive crisis: A single-center case series.. **2022**, e29695		1
122	Why medicines work.. **2022**, 238, 108175		1
121	A critical evaluation of crizanlizumab for the treatment of sickle cell disease.. *Expert Review of Hematology*, **2021**, 1-9	2.8	0
120	MPN and thrombosis was hard enough .˙.˙. now there's COVID-19 thrombosis too. **2021**, 2021, 710-717		0

119	Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease.. **2021**,		1
118	Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease mice.		
117	Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.. *Expert Review of Hematology*, **2022**, 1-12	2.8	0
116	Assessment of Reticulocyte and Erythrocyte Parameters From Automated Blood Counts in Vaso-Occlusive Crisis on Sickle Cell Disease.. **2022**, 9, 858911		0
115	High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells.. **2022**, 7, 14009-14016		0
114	Image_1.jpg. **2020**,		
113	Image_2.jpg. **2020**,		
112	Image_3.jpg. **2020**,		
111	Image_4.jpg. **2020**,		
110	Image_5.jpg. **2020**,		
109	Image_6.jpg. **2020**,		
108	Hämatologie und Onkologie. **2022**, 229-289		
107	Extinguishing the fire in sickle cell anemia.. *Blood*, **2022**, 139, 2578-2580	2.2	
106	Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review. **2022**,		0
105	Protocol for "Genetic composition of sickle cell disease in the Arab population: A systematic review".. *Health Science Reports*, **2022**, 5, e450	2.2	0
104	Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. **2022**, 12, 696		0
103	Carbon Monoxide and Sickle Cell Disease. **2022**, 482-496		
102	Validation of Patient-reported Vaso-occlusive Crisis Day as an Endpoint in Sickle Cell Disease Studies.. **2022**,		

101	A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease.. *Blood*, **2022**,	2.2	3
100	Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies. *Journal of Clinical Medicine*, **2022**, 11, 3118	5.1	1
99	Sickle Cell Disease, a Review. **2022**, 3, 341-366		
98	Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases. **2022**, 8, e09630		
97	Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease. *Journal of Clinical Medicine*, **2022**, 11, 3160	5.1	
96	28-Year-Old Man With Joint Pain. *Mayo Clinic Proceedings*, **2022**, 97, 1188-1193	6.4	
95	Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease. *Cells*, **2022**, 11, 1843	7.9	2
94	Sickle Cell Disease. *In Clinical Practice*, **2022**, 227-243	0	
93	Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease mice. *PLoS ONE*, **2022**, 17, e0261799	3.7	0
92	Sickle cell disease in children: an update of the evidence for WHO guideline development. *Archives of Disease in Childhood*, archdischild-2021-323633	2.2	
91	The oral ferroportin inhibitor vamifeport improved hemodynamics in a mouse model of sickle cell disease. *Blood*,	2.2	3
90	Voxelotor for the treatment of sickle cell disease in pediatric patients. *Expert Review of Hematology* , **2022**, 15, 485-492	2.8	0
89	Multiple and Single Reaction Monitoring Mass Spectrometry for Absolute Quantitation of Proteins. *Biochemistry*,		
88	Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?. *Health Science Reports*, **2022**, 5,	2.2	
87	Management of acute chest syndrome in patients with sickle cell disease: a systematic review of randomized clinical trials. *Expert Review of Hematology*, **2022**, 15, 547-558	2.8	
86	Liver to lung microembolic NETs promote Gasdermin-D-dependent inflammatory lung injury in Sickle Cell Disease. *Blood*,	2.2	7
85	Molecular Mechanisms of Hepatic Dysfunction in Sickle Cell Disease: Lessons From The Townes Mouse Model. *American Journal of Physiology - Cell Physiology*,	5.4	
84	Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study. *British Journal of Haematology*,	4.5	

83	Recent advances in sickle and niche research - Tribute to Dr. Paul S Frenette -. *Stem Cell Reports*, **2022**, 17, 1509-1535	8	0
82	Incidence and Predictors of Priapism Events in a Sickle Cell Anemia: A Diary-Based Analysis. *Blood Advances*,	7.8	0
81	Sickle Cell Disease. *JAMA - Journal of the American Medical Association*, **2022**, 328, 57	27.4	5
80	Reduced red cell transfusions and hospitalizations in sickle cell patients treated with voxelotor: Experience from a single center. *Transfusion*, **2022**, 62, 1462-1464	2.9	0
79	Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease. *Journal of Clinical Medicine*, **2022**, 11, 3856	5.1	
78	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. *Blood*,	2.2	2
77	Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials. **2022**, 27, 211-224		0
76	Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.		
75	Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients. 9,		0
74	Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative. 13,		1
73	Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease. **2022**, 119,		1
72	A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC).		1
71	Precision Medicine and Sickle Cell Disease. **2022**, 6, e762		0
70	Effective therapies for sickle cell disease: are we there yet?. **2022**,		0
69	Novel Strategies for the Treatment of COVID-19.		2
68	Cardiovascular consequences of sickle cell disease. **2022**, 3, 031302		
67	Splanchnic vein thrombosis associated with myeloproliferative neoplasms. **2022**, 218, 8-16		3
66	Hemoglobinopathies and Thalassemias. **2023**, 143-172		

65	Hematologic Diseases. **2022**, 38-43	0
64	Acute and chronic pain management in patients with sickle cell disease in the modern era: A comprehensive review. **2022**, 103533	0
63	Aberrant Sialylation in Cancer: Therapeutic Opportunities. **2022**, 14, 4248	3
62	Under the hood: The molecular biology driving gene therapy for the treatment of sickle cell disease. **2022**, 103566	0
61	Sickle cell disease in the new era: Advances in drug treatment. **2022**, 103555	0
60	Crizanlizumab to prevent crises in sickle cell disease. **2022**, 33, 34-35	0
59	Hydroxyurea (hydroxycarbamide) for sickle cell disease. **2022**, 2022,	3
58	Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine. **2022**, 10, 123	0
57	Comprehensive guide to managing a chronic automated red cell exchange program in sickle cell disease. **2022**, 37, 497-506	0
56	Rates of Opioid Misuse Amongst Patients Receiving Pain Management for Sickle Cell Disease in An Urban Setting. 089719002211283	0
55	NETs in sickle cell disease, quo vadis?. **2022**, 140, 938-939	0
54	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. 9,	1
53	Global perspectives on cellular therapy for children with sickle cell disease. **2022**, 29, 275-280	2
52	Investigation of thrombin generation assay to predict vaso-occlusive crisis in adulthood with sickle cell disease. 9,	0
51	Building a better NET : Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders. **2022**, 6,	1
50	Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model. **2022**,	0
49	Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. **2022**, 2022, 1-26	0
48	Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice.	0

47	Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease. **2022**, 27, 6835	0
46	Neutrophils as drivers of vascular injury in sickle cell disease.	1
45	An Overview of Solid Organ Transplantation in Patients With Sickle Cell Disease. Publish Ahead of Print,	0
44	Update on Treatment Options for Stuttering Priapism.	0
43	Novel approaches to antiplatelet therapy. **2022**, 206, 115297	0
42	Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. 1-12	0
41	Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers. **2022**, 36, 1077-1095	0
40	Sickle Cell Disease and the Kidney. **2022**, 36, 1239-1254	0
39	Genetic Modifiers of Sickle Cell Disease. **2022**, 36, 1097-1124	0
38	The Evolving Landscape of Drug Therapies for Sickle Cell Disease. **2022**, 36, 1285-1312	0
37	Applications and challenges for CRISPR/Cas9-mediated gene editing. **2022**,	0
36	The interplay of sleep disordered breathing, nocturnal hypoxemia, and endothelial dysfunction in sickle cell disease. **2023**, 68, 101602	0
35	Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report. 9,	0
34	Development of curative therapies for sickle cell disease. 9,	1
33	Plasma levels of E-selectin are associated with retinopathy in sickle cell disease.	0
32	Can Crude Oil Exploration Influence the Phytochemicals and Bioactivity of Medicinal Plants? A Case of Nigerian Vernonia amygdalina and Ocimum gratissimum. **2022**, 27, 8372	0
31	UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease.	0
30	Adhesion molecules and cerebral microvascular hemodynamic abnormalities in sickle cell disease. 13,	0

29	Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.	0
28	Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review. **2022**, 15, 1045-1054	0
27	Epidemiology and treatment of priapism in sickle cell disease. **2022**, 2022, 450-458	0
26	Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction. **2023**, 15,	0
25	Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre.	0
24	Evidence-Based Minireview: How to utilize new therapies for sickle cell disease. **2022**, 2022, 283-285	0
23	Rise of the planet of rare anemias: An update on emerging treatment strategies. 9,	0
22	Inflammatory status in pediatric sickle cell disease: Unravelling the role of immune cell subsets. 9,	0
21	Design of an adaptive randomized clinical trial of intravenous citrulline for sickle cell pain crisis in the emergency department. **2023**, 32, 101077	0
20	Outcomes and Barriers to Use of Novel Sickle Cell Therapeutic Agents in a Community Health Center. 8, 1-5	0
19	Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach. **2022**,	0
18	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. **2023**, 11, 338	0
17	Stem Cell-Based Therapeutic Approaches in Genetic Diseases. **2023**,	0
16	The Kidney in Sickle Cell Disease. **2023**, 849-863	0
15	The Prevalence of Cardiovascular Manifestations in Pediatric Sickle Cell Anemia Patients in a Large Tertiary Care Hospital in the Western Region of Saudi Arabia. **2023**,	0
14	The role of platelets in immune-mediated inflammatory diseases.	0
13	Targeting SELPLG/ P-selectin glycoprotein ligand 1 in preclinical ARDS: Genetic and epigenetic regulation of the SELPLG promoter. **2023**, 13,	0
12	Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular level. **2023**, 27, 133-149	0

11	A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care. **2023**, 7, e842	0
10	Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review. 10,	0
9	In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell□Related Injury. **2023**, 7, e848	0
8	Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies. **2023**, 40, 317-334	0
7	Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy. **2023**, 39, 555-565	0
6	A Review of CRISPR Cas9 for SCA: Treatment Strategies and Could Target □globin Gene and BCL11A Gene using CRISPR Cas9 Prevent the Patient from Sickle Cell Anemia?. **2023**, 11, 1-12	0
5	Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.	0
4	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice □Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278	0
3	Open-label, Multicenter, Phase 2 Study of a Food Enriched with Docosahexaenoic Acid in Adults with Sickle Cell Disease. **2023**, 102574	0
2	Recent progress in the treatment of sickle cell disease: an up-to-date review. **2023**, 12,	0
1	Effects of GBT1118 , a voxelotor analog, on intestinal pathophysiology in sickle cell disease.	0